Clinical Infectious Diseases · 2006 · 110 citations · 13 references
Veterinary MedicineInfectious DiseasesMicrobiologyHepatologyInfectious Disease EpidemiologyVirologyLiver DiseaseViral HepatitisDisease Onset TimingHepatitis C InfectionInfection Risk FactorsInfectious HepatitisSymptomatic Disease PrevalenceTransmission Risk Factors
BACKGROUND: The epidemiology of acute hepatitis C has changed during the past decade in Western countries. Acute HCV infection has a high rate of chronicity, but it is unclear when patients with acute infection should be treated. METHODS: To evaluate current sources of hepatitis C virus (HCV) transmission in Italy and to assess the rate of and factors associated with chronic infection, we enrolled 214 consecutive patients with newly acquired hepatitis C during 1999-2004. The patients were from 12 health care centers throughout the country, and they were followed up for a mean (+/- SD) period of 14+/-15.8 months. Biochemical liver tests were performed, and HCV RNA levels were monitored. RESULTS: A total of 146 patients (68%) had symptomatic disease. The most common risk factors for acquiring hepatitis C that were reported were intravenous drug use and medical procedures. The proportion of subjects with spontaneous resolution of infection was 36%. The average timespan from disease onset to HCV RNA clearance was 71 days (range, 27-173 days). In fact, 58 (80%) of 73 patients with self-limiting hepatitis experienced HCV RNA clearance within 3 months of disease onset. Multiple logistic regression analyses showed that none of the variables considered (including asymptomatic disease) were associated with increased risk of developing chronic hepatitis C. CONCLUSIONS: These findings underscore the importance of medical procedures as risk factors in the current spread of HCV infection in Italy. Because nearly all patients with acute, self-limiting hepatitis C--both symptomatic and asymptomatic--have spontaneous viral clearance within 3 months of disease onset, it seems reasonable to start treatment after this time period ends to avoid costly and useless treatment.
13
Treatment of Acute Hepatitis C with Interferon Alfa-2b
Elmar Jaeckel, Markus Cornberg, Heiner Wedemeyer et al. · New England Journal of Medicine · 2001 · 802 citations · Full text
J. Tilman Gerlach, Helmut M. Diepolder, Norbert H. Gruener et al. · Gastroenterology · 2003 · 521 citations · Full text
Differential regulation of cyclins D1 and D3 in hepatocyte proliferation
David G. Rickheim, Christopher J. Nelsen, John Fassett et al. · Hepatology · 2002 · 111 citations · Full text